Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 9/20 | 0.66 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.51 |
| ▸ | PYGL | P06737 | 1/20 | 0.47 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2454394 | 1.00 | GBA1 (0.66) | GBA1FUCA1PYGLS1PR5 | |
| SCHEMBL403643 | 1.00 | GBA1 (0.66) | GBA1FUCA1PYGLS1PR5 | |
| SCHEMBL500382 | 0.90 | GBA1 (0.58) | GBA1FUCA1S1PR5 | |
| SCHEMBL500383 | 0.90 | GBA1 (0.58) | GBA1FUCA1S1PR5 | |
| SCHEMBL8172188 | 0.88 | GBA1 (0.58) | GBA1PYGL | |
| SCHEMBL13090657 | 0.88 | FUCA1 (0.50) | GBA1FUCA1S1PR5 | |
| SCHEMBL587335 | 0.88 | FUCA1 (0.50) | GBA1FUCA1S1PR5 | |
| SCHEMBL13090653 | 0.87 | GBA1 (0.49) | GBA1FUCA1S1PR5 | |
| SCHEMBL17351179 | 0.86 | GBA1 (0.55) | GBA1FUCA1S1PR5 | |
| SCHEMBL591470 | 0.86 | GBA1 (0.55) | GBA1FUCA1S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2416656-B1 | METHODS FOR PREVENTING AND/OR TREATING LYSOSOMAL STORAGE DISORDERS | AMICUS THERAPEUTICS INC (US) | 2015-12-23 | — | — | EP | disclosed |
| US-8940766-B2 | Methods for preventing and/or treating lysosomal storage disorders | AMICUS THERAPEUTICS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8940766-B2 | Methods for preventing and/or treating lysosomal storage disorders | AMICUS THERAPEUTICS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| EP-2416655-B1 | METHODS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | AMICUS THERAPEUTICS INC (US) | 2014-06-25 | — | — | EP | disclosed |
| US-8304429-B2 | Methods for preventing and/or treating degenerative disorders of the central nervous system | AMICUS THERAPEUTICS, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-8304429-B2 | Methods for preventing and/or treating degenerative disorders of the central nervous system | AMICUS THERAPEUTICS, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-20120065153-A1 | AZASUGAR DERIVATIVES, HEPARANASE INHIBITORS, METHOD FOR PREPARING SAME, COMPOSITIONS CONTAINING SAME, USE THEREOF | SANOFI-AVENTIS (FR) | 2012-03-15 | — | — | US | disclosed |
| EP-2416656-A1 | METHODS FOR PREVENTING AND/OR TREATING LYSOSOMAL STORAGE DISORDERS | Amicus Therapeutics, Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| EP-2416655-A1 | METHODS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | Amicus Therapeutics, Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| US-20100261753-A1 | METHODS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | AMICUS THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100261753-A1 | METHODS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | AMICUS THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| WO-2010118283-A1 | METHODS FOR PREVENTING AND/OR TREATING LYSOSOMAL STORAGE DISORDERS | AMICUS THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010118282-A1 | METHODS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | AMICUS THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100260740-A1 | METHODS FOR PREVENTING AND/OR TREATING LYSOSOMAL STORAGE DISORDERS | AMICUS THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100260740-A1 | METHODS FOR PREVENTING AND/OR TREATING LYSOSOMAL STORAGE DISORDERS | AMICUS THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-20070270354-A1 | Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof | SANOFI-AVENTIS (FR) | 2007-11-22 | — | — | US | disclosed |
| US-6046214-A | USEFUL IN TREATMENT AND/OR PREVENTION OF DIABETES, AND ESPECIALLY NON-INSULIN DEPENDENT DIABETES (NIDDM OR TYPE 2 DIABETES) INCLUDING OVERNIGHT OR MEAL TREATMENT AND TREATMENT OR PREVENTION OF LONGTERM COMPLICATIONS, SUCH AS RETINOPATHY | NOVO NORDISK A/S (DK) | 2000-04-04 | — | — | US | disclosed |
| EP-0983239-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998050359-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065153-A1 | AZASUGAR DERIVATIVES, HEPARANASE INHIBITORS, METHOD FOR PREPARING SAME, COMPOSITIONS CONTAINING SAME, USE THEREOF | HPSE, HAAO, HEXD | GBA1 135/4885FUCA1 42/4885PYGL 719/4885 |
| US-20100261753-A1 | METHODS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | SNCA, BDNF, PARK7 | GBA1 71/4885FUCA1 727/4885PYGL 1683/4885 |
| US-20100260740-A1 | METHODS FOR PREVENTING AND/OR TREATING LYSOSOMAL STORAGE DISORDERS | GBA1, GAA, MAN2B1 | GBA1 1/4885FUCA1 156/4885PYGL 856/4885 |
| US-20070270354-A1 | Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof | HPSE, HAAO, HEXD | GBA1 135/4885FUCA1 39/4885PYGL 682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.